Close Menu

More articles about Clinical Proteomics

Progenetics will distribute GeneStrat and Veristrat liquid biopsy tests in Israel, making Biodesix's tests available in the Middle East for the first time.

The company plans to use the proceeds to support research collaborations and to expand its commercial team.

The two studies were part of larger project aimed at building a complete map of mitochondrial function and associated proteins. 

The results support a survival benefit for patients treated with therapies guided by combined DNA and mRNA sequencing and protein expression analyses. 

The assay is designed to measure changes in blood levels of the peptide precursor procalcitonin to differentiate bacterial infections from viral ones. 

Researchers also uncovered key pathways and alterations linked to differences in survival.

Along with scientists from the University of Leicester, the researchers picked the Xevo TQ-S micro platform to do a pilot study on heart failure patient samples.

The Swiss firm's assay combines a 29-gene host immune response panel with two tumor-derived proteins to detect early-stage colorectal cancer and large adenomatous polyps.

The company did not specify the number of shares it will offer or the offering price, but said it intends to trade on the Nasdaq Global Market.

The supply agreement was originally established between BG and the now defunct Health Diagnostics Laboratory, which was formerly BG's biggest customer.

Researchers from Protagen, Targos, and elsewhere have identified autoantibody biomarkers specific to patients diagnosed with prostate cancer.

The company said it plans to launch a clinical trial to validate its Immray PanCan-d blood test in both Europe and the US.

While much attention has focused on triple quads, MALDI-TOFs offer advantages in simplicity and throughput that could help them make clinical inroads.

The decision lets Vermillion access Medi-Cal's patient network, which covers more than 12.6 million lives, or roughly a third of California's covered lives.

In a large, prospective study published in Lancet Oncology, the screening assay was projected to reduce the number of prostate biopsies by 32 percent.

The company presented new data at a meeting last week showing that Vectra DA predicted whether patients would do better on one or the other of two possible second-line therapies.

The sensor features a DNA-based steric hindrance method, and can detect the presence of antibodies in whole blood in less than 10 minutes.

The deal provides Sciex with the rights to commercialize immune-MRM technology developed by Amanda Paulovich's laboratory.

OncoPlex operates a CAP-accredited and CLIA-certified laboratory and provides mass spectrometry-based tumor profiling services.

The funding will be used to further expand the company's clinical testing products and services in the US and abroad.

Pages

Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.

Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.

The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.

In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.